Clinical trials · Riverside–San Bernardino, CA
Chronic Graft Versus Host Disease clinical trials in Riverside–San Bernardino
We’re tracking 16 recruiting chronic graft versus host disease studies with a site in or near Riverside–San Bernardino — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Riverside–San Bernardino
- NCT01804686RecruitingPhase 3
Long-term ibrutinib follow-up with or without nivolumab
This study looks at how safe and effective ibrutinib is over the long term, either alone or together with nivolumab. You may join if you are already in an earlier ibrutinib study and your care team feels staying on ibrutinib is worth the risk.
Orange, CaliforniaAges 18 years+ - NCT06619561RecruitingPhase 2
Testing vimseltinib for chronic graft versus host disease
This trial tests a new drug called vimseltinib for people with active chronic graft versus host disease (cGVHD) that hasn't gotten better after at least two prior treatments. The goal is to see if vimseltinib can help control the condition.
Orange, CaliforniaAges 18 years+ - NCT07124078RecruitingPhase 2
Study of axatilimab for young people with chronic graft-versus-host disease
This study tests a new drug called axatilimab for children and teens with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The goal is to see if axatilimab works better than the usual care options. Participants will be randomly assigned to receive either axatilimab or one of several standard treatments.
Duarte, CaliforniaAges 2–17 - NCT06815003RecruitingPhase 2
Preventing Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Duarte, CaliforniaAges 18–80 - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Duarte, CaliforniaAges 18–66 - NCT04710576RecruitingPhase 2
Axatilimab for chronic graft-versus-host disease
This trial tests a new drug called axatilimab to help patients whose chronic graft-versus-host disease (a condition where transplanted immune cells attack the body) isn't responding well to standard treatments. Researchers want to find the right dose and see if it can improve symptoms and quality of life.
Duarte, CaliforniaAges 2 years+ - NCT07025538RecruitingPhase 1
Preventing chronic graft-versus-host disease with ruxolitinib
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
Duarte, CaliforniaAges 18 years+ - NCT06585774RecruitingPhase 3
Axatilimab plus steroids for new chronic GVHD
This study tests a new drug called axatilimab combined with steroids as a first treatment for chronic graft-versus-host disease (GVHD) after a stem cell transplant. It aims to see if this combination helps control symptoms better than steroids alone.
Duarte, CaliforniaAges 12 years+ - NCT06343792RecruitingPhase 2
Testing RLS-0071 for steroid-resistant acute graft-versus-host disease
This trial tests a new drug, RLS-0071, for people who are hospitalized with acute graft-versus-host disease that hasn't improved with steroids. It aims to see if the drug is safe and can help control the condition.
Duarte, CaliforniaAges 12 years+ - NCT06936566RecruitingPhase 2
Ruxolitinib for graft-versus-host disease after transplant
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
Duarte, CaliforniaAges 18 years+ - NCT05436418RecruitingPhase 1/Phase 2
Lower-dose transplant medicines to prevent graft-versus-host disease
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
Duarte, CaliforniaAges 12–120 - NCT04380740RecruitingPhase 2
Longer vs shorter abatacept doses to prevent graft-versus-host disease
This trial tests whether giving abatacept for a longer or shorter time can better prevent graft-versus-host disease (a common complication after a stem cell transplant). If you’re having a planned unrelated donor transplant, the results may help reduce the risk or severity of transplant-related immune problems.
Duarte, CaliforniaAges 2 years+ - NCT05919511Recruiting
Questionnaire study for people at risk after stem cell transplant
This observational study follows people who had a stem cell transplant a few months ago to better understand risk for chronic graft-versus-host disease. You won’t get a study treatment; instead, you’ll complete questionnaires over time, and the study team looks at your symptoms and experiences.
Duarte, CaliforniaAges 18 years+ - NCT05996627RecruitingPhase 2
Belumosudil for early treatment of chronic graft-versus-host disease
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
Duarte, CaliforniaAges 18 years+ - NCT03779854RecruitingPhase 2
Preventing graft-versus-host disease in kids after stem cell transplant
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
Los Angeles, CaliforniaAges 6 months–26 years - NCT07116031RecruitingPhase 2
Belumosudil for children with chronic GVHD
This study tests a new medicine called belumosudil for children with chronic graft-versus-host disease (GVHD) that hasn't improved with at least 2 other treatments. The goal is to see if it can help control the disease and improve symptoms.
Los Angeles, CaliforniaAges 1–18
Hear when a new Chronic Graft Versus Host Disease trial opens near Riverside–San Bernardino, CA
We’ll email you when one opens near Riverside–San Bernardino, CA — at most once a week, no account needed, unsubscribe anytime.
Chronic Graft Versus Host Disease trials in other cities
Where these studies are running near Riverside–San Bernardino
Institutions with a site for the recruiting chronic graft versus host disease studies listed above.
- City of Hope Comprehensive Cancer Center · 13 studies
- Children's Hospital Los Angeles · 3 studies
- University of California, Los Angeles (UCLA) · 2 studies
- Keck Medicine of USC
- Site 1091
- Site 1343
- St. Joseph Hospital Center for Cancer Prevention and Treatment
- UCLA Medical Center
What taking part in a chronic graft versus host disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting chronic graft versus host disease studies in California.
Common questions
- Are there chronic graft versus host disease clinical trials near Riverside–San Bernardino?
- Yes. We're currently tracking 16 recruiting chronic graft versus host disease studies with a site near Riverside–San Bernardino, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a chronic graft versus host disease study near Riverside–San Bernardino?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Riverside–San Bernardino to take part?
- Not necessarily. These studies have a site near Riverside–San Bernardino, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a chronic graft versus host disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New chronic graft versus host disease studies open near Riverside–San Bernardino regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.